Security
PURPLE BIOTECH LTD Ordinary Shares · KITVF
KITVFOTCCommon stockHistorical · closed Jul 29, 2022CIK 1614744Updated Oct 6, 2026
Name history
Kitov Pharma Ltd. · through Dec 10, 2020Kitov Pharmaceuticals Holdings Ltd. · through Dec 21, 2017
KITVF price & chart
Historical security
This listing closed Jul 29, 2022. Live provider charts are shown only for current listings.
About the company
We are a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance.
In the news
No coverage from other publishers is available.
Financials
FY 2025 · USDSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -26,492,000Source | -7,279,000Source | 19,977,000Source | 21,760,000Source |
| Additional Financial Items | ||||
| AdjustmentsForFinanceIncomeUSD | 966,000Source | 3,726,000Source | — | — |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | 450,000Source | -2,076,000Source | 1,334,000Source | 799,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 309,000Source | 582,000Source | 1,875,000Source | 2,412,000Source |
| GeneralAndAdministrativeExpenseUSD | — | — | — | 1,644,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 23,000Source | 44,000Source | 56,000Source | 67,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 217,000Source | 183,000Source | 168,000Source | 165,000Source |
| ProceedsFromIssuingSharesUSD | 3,153,000Source | 5,809,000Source | 1,563,000Source | 1,498,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | — | 202,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | 3,245,000Source | 3,183,000Source | 5,237,000Source | 6,283,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.23Source | 0.23Source | 0.23Source | 0.23Source |
| BasicEarningsLossPerShareUSD per share | 0.03Source | 4.44Source | 22,133,294Source | — |
| DilutedEarningsLossPerShareUSD per share | 0.03Source | 4.99Source | 22,133,294Source | — |
| FinanceCostsUSD | 982,000Source | 483,000Source | -2,195,000Source | 67,000Source |
| FinanceIncomeUSD | 424,000Source | 868,000Source | -992,000Source | 910,000Source |
| GeneralAndAdministrativeExpenseUSD | — | — | — | 1,644,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 35,000Source | 23,000Source | 37,000Source | 49,000Source |
| OtherFinanceCostUSD | — | — | 2,126,000Source | 67,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | 234,000Source | 322,000Source | 401,000Source | — |
| ProfessionalFeesExpenseUSD | — | 2,850,000Source | 1,500,000Source | 1,440,000Source |
| ProfitLossAttributableToNoncontrollingInterestsUSD | -106,000Source | -39,000Source | 97,000Source | 92,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | -26,386,000Source | -7,240,000Source | 19,880,000Source | 21,668,000Source |
| ProfitLossFromOperatingActivitiesUSD | — | — | -22,271,000Source | — |
| ResearchAndDevelopmentExpenseUSD | 3,731,000Source | 7,620,000Source | 17,034,000Source | 16,320,000Source |
Offerings
Registration 333-296088
Registration 333-289927
- Gross proceeds
- 5999704.5
- Net proceeds
- 5579704.57
- Deal price
- 1.0
- Shares
- 5999704
- Offering amount
- $30,000
- Offering price
- $1.00
- Ticker
- PPBT
Filing attachments
ea030419201ex99-1.htm · 6-K · 2026-09-02
Exhibit 99.1 New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice o…
Read attachment ↗ea030114201ex99-1.htm · 6-K · 2026-08-10
Exhibit 99.1 CORPORATE PRESENTATION August 2026 Advancing the Next Generation of Immuno-oncology NASDAQ/TASE: PPBT 2 Forward-looking Statements and Safe Harbor Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statement…
Read attachment ↗ea030094001ex99-1.htm · 6-K · 2026-08-07
Exhibit 99.1 Purple Biotech Reports Second Quarter 2026 Financial Results New preclinical data presented at European Association for Cancer Research (EACR) 2026 Annual Congress, which further validates the differentiated profile of IM1240’s anti-tumor activity, favorable safety and pharmacokinetic profile, and broad therapeutic window IM1240 tri-specific antibody (capped-CD3x5T4xNKG2A) is aimed at entering clinical studies in 2027 Total Cash Position of $6.1 million as of June 30, 2026, prov…
Read attachment ↗ea030094001ex99-2.htm · 6-K · 2026-08-07
Exhibit 99.2 Purple Biotech Ltd. Condensed Consolidated Unaudited Interim Financial Statements As of June 30, 2026 Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2026 ────────────────────────────────────────────────────────────── Contents Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 1 2026 Condensed Consolidated Unaudited Interim Statements of Financial Position 2 Condensed Consolidated Unaudited…
Read attachment ↗ea029956701ex99-1.htm · 6-K · 2026-07-29
Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the “Meeting”) of Purple Biotech Ltd. (the “Company”) will be held on Tuesday, September 8, 2026, at 4:30 p.m. Israel time at the Company’s executive offices at 4 Oppenheimer Street, Science Park, Rehovot, Israel, for the following purposes: To elect each of Mr. Gil Efron and Ms. Yael Margolin as members of the second class of directors of the Board of Direc…
Read attachment ↗ea029956701ex99-2.htm · 6-K · 2026-07-29
Exhibit 99.2 VOTING SLIP FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS Company name: Purple Biotech Ltd., company no. 520031238 Company address (for submission and delivery of Voting Slips): 4 Oppenheimer Street, Science Park, Rehovot 6701101, Israel, Attn.: Gil Efron, Chief Executive Officer Meeting date: Tuesday, September 8, 2026, at 4:30 p.m. (Israel time). Meeting type: Annual General Meeting (the “Meeting”). Record Date: Monday, August 3, 2026 Shareholder details: Shareholder name: …
Read attachment ↗